A therosclerosis is a chronic and multifactorial disease mediated by complex interplay between resident endothelial cells, vascular smooth muscle cells (VSMCs), and infiltrating macrophages. Environmental exposure to risk factors such as hyperlipidemia throughout the development of atherosclerosis causes vascular remodeling and in turn reduces arterial compliance. Although many drugs inhibiting vascular remodeling and metabolic disorder offer an effective therapeutic strategy for preventing atherosclerotic progression, none of these drugs are found to totally reverse atherosclerotic plaque in animal experiments.
A therosclerosis is a chronic and multifactorial disease mediated by complex interplay between resident endothelial cells, vascular smooth muscle cells (VSMCs), and infiltrating macrophages. Environmental exposure to risk factors such as hyperlipidemia throughout the development of atherosclerosis causes vascular remodeling and in turn reduces arterial compliance. Although many drugs inhibiting vascular remodeling and metabolic disorder offer an effective therapeutic strategy for preventing atherosclerotic progression, none of these drugs are found to totally reverse atherosclerotic plaque in animal experiments. 1, 2 Furthermore, clinical trials have revealed that intensive lipid-lowering treatment with rosuvastatin or atorvastatin only leads to limited plaque regression (1.22% and 0.99%, respectively), 3, 4 although routine statin treatments can significantly reduce >30% of the risk of major adverse cardiac events such as myocardial infarction. [5] [6] [7] [8] [9] The memory effects of atherosclerosis imply that the mechanisms for atherogenesis are partially independent of the risk factors. It seems that atherosclerosis would progress at its own pace, once the atherosclerotic plaques are formed. Epigenetic modifications refer to heritable changes in gene expression that are not coded in the DNA sequence itself. Studies demonstrate that epigenomic changes in tissues and cells play important roles in vascular remodeling and atherosclerosis. 10 DNA methylation is the most understood epigenetic modification. The effect of DNA methylation on gene expression can persist even if the risk factors are removed. In eukaryotic genomes, DNA methyltransferases (DNMTs) catalyze the conversion of cytosines, predominantly in cytidine phosphate guanosine (CpG) dinucleotides, to 5-methylcytosine (5-mC), and then silence gene expression. The DNMT inhibitor 5-aza-2′-deoxycytidine (5-aza) is proven to counteract the depressed expression of methylation genes and is currently approved for treatment of myelodysplastic syndrome. [11] [12] [13] [14] Interestingly, physiological demethylation also exists in vivo to balance the silencing effect on gene expression by DNA methylation. Even though no direct DNA demethyltransferases were identified, current studies showed that 5-mC can be oxidized to 5-hydroxymethylcytosine (5-hmC) by ten-eleven translocation (Tet) family of enzymes. 15, 16 Through the base excision repair pathway, 5-hmC is then converted to unmethylated cytosine, leading to demethylation and gene reactivation. [17] [18] [19] Previous studies had demonstrated that atherosclerosis occurred in familial aggregation, suggesting the role of genetic factors in atherogenesis. 20 Recent evidence supported an association between DNA methylation and cardiovascular diseases, such as atherosclerosis and vascular remodeling. [20] [21] [22] Dunn et al 23 uncovered that inhibition of DNA methylation attenuated atherosclerotic burden through ameliorating endothelial dysfunction and restoring mechanosensitive endothelial gene expression induced by oscillatory shear stress. On the other hand, several studies suggested that DNA methylation might participate in regulating VSMC phenotype and vascular remodeling. 24 Liu et al 25 reported a significant reduction in Tet2 expression in the neointima or coronary atherosclerotic plaques. Loss of Tet2 suppressed 5-hmC enrichment and affected the expression of VSMC differentiation marker genes, which in turn aggravated vascular remodeling. It is, thus, important to determine the role of DNA methylation changes in VSMCs and vascular remodeling.
In this study, we sought to study the DNA methylation state in different stages of atherosclerosis. We found that DNA methylation balance regulated by DNMT1 and Tet2 influenced VSMCs phenotype and vascular remodeling.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

DNMT Inhibitor Attenuated Atherosclerosis in ApoE −/− Mice
Because 5-aza has been proven to inhibit DNA methylation, we administrated 5-aza to ApoE −/− mice to confirm the effect of DNA demethylation on atherosclerosis. At first, we found that body weights were comparable at the indicated time points between vehicle-and 5-aza-treated group, indicating that drug treatment was well tolerated ( Figure I in the onlineonly Data Supplement). In addition, 5-aza treatment for 12 weeks had no remarkable effect on the plasma levels of lipid profiles and fasting glucose ( Figure II in the online-only Data Supplement). We then examined the effect of 5-aza on atherosclerosis. After 18 weeks exposure of 5-aza, atherosclerotic lesion area was significantly attenuated when compared with that in vehicle-treated ApoE −/− mice as demonstrated by en face Oil red O-positive area (20.1±2.2% versus 30.8±7.5%; P=0.016; Figure 1A and 1B) and by quantification of lesion area at the aortic root ( Figure 1C and 1D) .
We further examined whether 5-aza affected plaque composition. Masson staining demonstrated that necrotic core was smaller in 5-aza-treated ApoE −/− mice compared with vehicletreated ApoE −/− mice (22.0±4.2% versus 50.8±4.5%; P<0.01; Figure 1E through 1G). As shown in Figure 1E and 1F, 5-aza significantly reduced plaque macrophage content by >50% compared with vehicle-treated group (1.1±0.1% versus 2.8±0.2%; P<0.01). The relative contents of α-smooth muscle actin were similar between vehicle-and 5-aza-treated groups ( Figure 1H and 1I). However, the distribution of α-smooth muscle actin staining was diffuse in vehicle-treated ApoE −/− mice, which was restored in 5-aza-treated ApoE −/− mice ( Figure 1J and 1K).
DNMT Inhibition Dynamically Regulated DNA Methylation and Tet2 Expression in Atherosclerotic Aorta
Because epigenetic drift occurred during aging of certain tissue types, we next evaluated global methylation and hydroxymethylation levels in the aorta of ApoE −/− mice at different ages. In line with the findings derived from other tissues, we found that global DNA methylation, as opposed to global DNA hydroxymethylation, was gradually decreased with age both in aorta DNA of wild-type and ApoE −/− mice, which were fed with Western diet (Figure 2A and 2B) .
Because DNMT1, DNMT3a, and DNMT3b are the principal mediators of DNA methylation in mammalian cells, 26, 27 we determined the expression of DNMT proteins in atherosclerotic plaques. In the serial sections of aortic sinus stained with α-smooth muscle actin or F4/80 and immunofluorescence images, we found that DNMT1 was predominantly expressed in VSMCs, rather than in macrophages, in the plaque of ApoE −/− mice ( Figure 2C and 2D). DNMT3a was equivalently expressed in VSMCs and macrophages in plaque, whereas DNMT3b was undetectable in the cross sections from wildtype and ApoE −/− mice ( Figure 2C ). The inhibitory function of 5-aza depends on trapping DNMT1 in a covalent complex with DNA and also preferentially targets DNMT1 via ubiquitin-dependent proteasomal degradation. 11 The protein expression of DNMT1 and DNMT3a was higher in vehicle-treated ApoE −/− mice when compared with wild-type mice but was not affected by 5-aza treatment ( Figure 2E and 2F). However, DNMT3b was expressed in low level in 3 groups but rich in mouse heart ( Figure 2E ). This intriguing phenomenon prompted us to investigate the consequence of the enzyme activity of DNMT Figure 2G , the aortas dissected from vehicle-treated ApoE −/− mice had higher enzyme activities than the wild-type samples. Administration of 5-aza in turn suppressed the excessive DNMT activity by 2.76-fold. In keeping with the changes of DNMT activity, 5-mC content was significantly increased in vehicle-treated ApoE −/− mice but declined close to normal level when treated with 5-aza ( Figure 2H ). Collectively, these results suggested that the effect of 5-aza on DNA demethylation of the aorta containing atherosclerostic plaques was mediated via suppression of DNMT enzyme activity.
Given that Tet2 was the predominant DNA demethylation enzyme in arteries, 24 we firstly investigated the expression of Tet2 among 3 groups. Using our panel of mouse aorta samples, we tested the abundance of RNA transcripts and protein. As shown in Figure 2I and 2J, the expression of Tet2 was significantly reduced in the aorta of vehicle-treated ApoE −/− mice compared with wild-type group and restored after administration of 5-aza, which was inversely associated with DNMT activity.
Decreased Expression of Tet2 Attributed to Excessive Promoter Methylation
To clarify the underlying mechanisms of Tet2 expression, we applied methylation-specific polymerase chain reaction and pyrosequence to quantify methylation percentage at target CpG sites in the promoter of Tet2. The locations of Tet2 promoter and CpG islands were shown in Figure 3A . It was reported that the fragment containing high-density CpG sites within the promoter significantly correlated with transcription repression of downstream genes. Thus, we first screened the promoter region of Tet2. Within these fragments, we performed methylationspecific polymerase chain reaction to determine the methylation status and found that the methylation level of fragment 2 was higher in the aorta of vehicle-treated ApoE −/− mice than other 2 groups ( Figure 3B ). Using pyrosequencing, we further confirmed that the single methylation percentages at 7 of 8 target CpG sites, as well as the average methylation percentages of all sequencing CpG sites, were markedly elevated in vehicletreated ApoE −/− group than those in wild-type and 5-aza-treated 
DNMT Inhibitor Resulted in 5-hmC Enrichment at the Myocardin Promoter
Given that Tet2 was required for conversion from 5-mC to 5-hmC, the interim cytosine to unmethylated cytosine, so we analyzed global 5-hmC content and gene-specific hydroxymethylation. As shown in Figure 4A , global hydroxymethylation level was dramatically lower in vehicle-treated mice compared with other 2 groups. Because Liu et al 25 reported that knockdown of Tet2 caused a cascade of epigenetic changes in VSMC phenotypic genes, we wished to address the issue of whether demethylation of Tet2 promoter after 5-aza treatment mediated the methylation and hydroxymethylation status at the promoters of these genes. Gene-specific measurement of hydroxymethylation was determined by quantitative polymerase chain reaction using primers predesigned to the promoter region of Myocardin, Krüppel-like factor 4, and serum response factor (SRF). Compared with vehicle group, 5-aza treatment inhibited the methylation level at the Myocardin promoter with concomitant recruitment of 5-hmC in the corresponding region of Myocardin promoter ( Figure 4B and 4C). Accordingly, the mRNA expression of Myocardin was repressed in the aorta of vehicle-treated ApoE −/− mice but significantly reversed by 5-aza ( Figure 4D ). On the contrary, the 5-mC and 5-hmC contents at the indicated regions of Krüppel-like factor 4 and SRF promoters were not altered among 3 groups ( Figure IV 
DNMT1 Regulated VSMCs Proliferation, Migration, and Phenotype Switching
The altered Myocardin methylation in plaque implied that DNA hypermethylation may affect VSMC marker genes expression and impair VSMC function during atherosclerotic development. Inspired by the finding and hypothesis, we then determined the role of 5-aza on VSMC function in vitro. It was known that VSMCs proliferation and migration into the intima were imperative steps for atherosclerosis and restenosis. 28 As an initial step, we examined the effect of 5-aza on DNMT activity and global 5-mC content in rat aortic smooth muscle cells (RASMCs). RASMCs were treated with 1 and 5 μmol/L of 5-aza, which did not affect cell viability (Figure V in the onlineonly Data Supplement). Although administration of 5-aza did not affect the expression of DNMT1 and DNMT3a stimulated by platelet-derived growth factor (PDGF), the DNMT activity was profoundly repressed by 5-aza treatment ( Figure 5A through 5D). Accordingly, incremental 5-mC content induced by PDGF was decreased after 5-aza treatment ( Figure 5E ). We next determined the role of 5-aza in the proliferation and migration of RASMCs. Scratch assays were performed to evaluate the role of 5-aza in SMCs migration. As shown in Figure 5F and 5G, administration of 5-aza for 3 days significantly suppressed PDGF-induced migration of RASMCs. As shown in Figure 5H , treatment of RASMCs with 5-aza significantly inhibited PDGFinduced proliferation in a time-and dose-dependent manner.
Our in vivo observation had displayed a significant reduction of Myocardin expression in the aortas of ApoE −/− mice after 5-aza treatment. Thus, we next studied the effect of 5-aza on VSMC phenotype modulation. After treatment of RASMCs with 5-aza for ≤5 days, the mRNA expression of VSMC differentiation marker genes, such as smooth muscle α-actin, smooth muscle-myosin heavy chain, and Myocardin, was markedly reversed 1.5-fold to 4-fold when compared with the decreased expression levels induced by PDGF ( Figure 5I ). Accordingly, the protein expression of these genes was restored by 5-aza treatment ( Figure 5J ). Moreover, the morphological analysis demonstrated that PDGF induced a flattened shape and a moderately larger size that reflected a dedifferentiated state of VSMCs. In contrast, administration of 5-aza kept VSMCs in a spindle-like shape that reflected a differentiated state ( Figure 5K ). We then measured the cell surface area among 3 groups, finding that much larger VSMCs in PDGF-treated group compared with vehicle group and smaller VSMCs in 5-aza-treated group compared with PDGF-treated group, respectively ( Figure 5L) . Together, these data demonstrated that inhibition of DNA methylation retarded VSMCs proliferation and migration through suppression of VSMC plasticity. 
Effects of DNMT Inhibitor on Neointimal Formation
Even though 5-aza could inhibit VSMC proliferation, migration, and dedifferentiation in vitro, it was still required to validate the effect of 5-aza on VSMC functions and vascular remodeling in vivo. For this purpose, complete ligation of common carotid artery was performed to induce extensive neointimal formation in the presence of an intact endothelial lining. First and foremost, we determined the expression levels of DNMT1 and DNMT3a in vitro. DNMT1 was highly expressed in RASMC but almost undetectable in macrophages, whereas DNMT3a was comparably expressed in RASMC and macrophages ( Figure 6A ). We then characterized the pattern of expression of DNMT1 and DNMT3a in mouse neointimal formation model at 21 days after carotid artery ligation. Immunohistochemistry analysis showed that DNMT1 was widely expressed in the medial and neoinitmal layers, whereas DNMT3a was predominantly localized in the neointimal layer ( Figure 6B ). In contrast, DNMT1 and DNMT3a were not yet observed in the sham arteries.
The stimulation of DNMT1 and DNMT3a in response to vascular injury promoted us to gain further insight into the effect of DNA demethylation in neointimal formation. Vehicle or 5-aza (1 mg/kg) was intraperitoneally injected daily for 3 weeks after carotid ligation. We did not find any death in 5-aza-treated group. The body weights between saline-and 5-aza-treated groups were also comparable (19.2±0.8 versus 18.6±0.9 g; P=0.39). After harvesting the carotid arteries, we found that 5-aza substantially inhibited neointima formation ( Figure 6C ), which was associated with a decrease in both neointimal area (2.25±0.14×10 4 versus 4.07±0.22×10 4 μm 2 ; P<0.01; Figure 6D ) and the intima-to-media ratio (0.20±0.02 versus 0.44±0.03; P<0.01; Figure 6E ). Likewise, immunohistochemistry staining and quantitative analysis showed a 4-fold increase in the proportion of Tet2-positive cells within the neointimal layer of 5-aza-treated group ( Figure 6F and 6G) .
Knockdown of DNMT1 Suppressed VSMCs Proliferation, Migration, and Dedifferentiation
We next sought to determine which isoforms of DNMT enzymes were involved in VSMC differentiation, proliferation, and migration. First, we confirmed the small interfering RNA (siRNA) inhibitory efficiency because the expression of DNMT1 and DNMT3a were downregulated by 63.4% and 59.9%, respectively, in protein level ( Figure 7A) . Indeed, when compared with DNMT3a, the knockdown of DNMT1 more efficiently abolished DNMT enzyme activities along with 5-mC content (5.6±2.7% versus 13.6±5.7%; P=0.042; Figure VI in the online-only Data Supplement). We then examined whether DNMT1 or DNMT3a specifically mediated VSMC proliferation and migration. PDGF-induced proliferation was significantly inhibited by siDNMT1 but not siDNMT3a ( Figure 7B ; Figure VIIA in the online-only Data Supplement). Likewise, DNMT1 knockdown dramatically attenuated VSMCs migration stimulated by PDGF ( Figure 7C and 7D). Nevertheless, no significant changes were observed in VSMC migration when treated by DNMT3a siRNA ( Figure VIIB and VIIC in the online-only Data Supplement). Furthermore, the elevated expression levels of VSMCs dedifferentiation marker genes induced by PDGF were decreased after transfection with DNMT1-specific siRNA for 48 hours ( Figure 7E ). Nonetheless, DNMT3a siRNA had no impact on PDGF-induced VSMCs differentiation ( Figure VIID in the online-only Data Supplement).
Depletion of DNMT1 Restored Tet2 Expression and Suppressed Tet2 Methylation
We further investigate the effect of 5-aza and DNMT1 on Tet2 observed in mice model. Although PDGF inhibited Tet2 expression in a time-dependent manner, the administration of 5-aza for 3 and 5 days significantly restored Tet2 expression in RASMCs (P=0.013 and P=0.004, respectively; Figure 8A ). The methylation levels of Tet2 promoter in RASMCs were then evaluated by quantitative methylation-specific polymerase chain reaction. Consistent with increased Tet2 expression after incubation with 5-aza, the methylation levels of Tet2 promoter were suppressed by 5-day treatment of 5-aza ( Figure 8B) .
Inspired by the role of 5-aza on the inhibition of 5-mC content and Tet2 expression, we further discussed the reciprocal effect between DNMT1 and Tet2. Although depletion of DNMT1 increased Tet2 expression ( Figure 8C ), knockdown of Tet2 did not conversely affected DNMT1 expression ( Figure 8D) . Likewise, when compared with control siRNA, 
Discussion
In this study, we showed that DNA methylation was increased, whereas DNA hydroxymethylation, 1 intermediate form for demethylation, was decreased in atherosclerotic aorta. The increased global methylation could be explained by the enhanced activity of DNMT1 and reduced expression of Tet2. However, administration with 5-aza would restore aberrant hypermethylation both in global level and within the promoter of Tet2. As a consequence, 5-hmC was recaptured within the promoter of Myocardin, which promoted differentiation of VSMCs and inhibited the vascular remodeling ( Figure IX in the online-only Data Supplement).
The clinical relevance of DNA methylation firstly became apparent in relation to cancer. 29 Then the abnormal DNA methylation was also found associated with other diseases such as Rett syndrome, immune deficiency, and so on. 30 ,31 Some changes of DNA methylation can be a physiological response to environmental changes, whereas others might be associated with a pathological process such as cell phenotype change or even malignant transformation. 16 VSMCs can revert to a synthetic phenotype featuring highly proliferative and migratory activity and increased synthesis of inflammatory factors. We find that DNMT activities differ along with atherosclerotic progression, although DNMT1 and Tet2 influence the DNA methylation equilibrium and SMC phenotype. Furthermore, to preclude other confounding factors, we apply a carotid artery ligation model in which abnormalities in VSMCs are primarily responsible for vascular remodeling. The observation that 5-aza treatment inhibits neointimal formation confirms our assumption that 5-aza inhibits vascular remodeling via DNA demethylation in VSMCs.
As reviewed elsewhere, 2 pathways involve the DNA demethylation. [30] [31] [32] One is passive demethylation, which is largely acquired by the inhibition of DNMTs activity. On the other side, the process of active conversion and removal of 5-mC is referred to as active demethylation. About the latter, mounting evidence has accumulated that Tet enzyme family serves as keys for the conversion of 5-mC to 5-hmC. Together with the established pharmacological action of 5-aza and our current finding, the effect of 5-aza on Tet2 expression could be explained by the mechanism that 5-aza is recruited into the hypermethylated fragments, forming covalent bonds with DNMT1 and causing DNMT1 enzyme inactivation. As a consequence of 5-aza incorporation, DNMT1 fails to combine with Tet2 promoter and maintain Tet2 methylation, eventually resulting in the recovery of Tet2 expression and the elevation of global 5-hmC levels. These results suggest that DNMT inhibitor, 5-aza, reverses DNA hypermethylation in atherosclerotic aorta of ApoE −/− mice not only through inhibition of DNMT activity and traditional passive demethylation but also indirectly through recovery of Tet2 expression and active demethylation. However, based on analyses of recent evidence from our and other laboratories, we could not postulate which pathway predominates after 5-aza treatment.
DNA demethylation regulated by the Tet family is important for physiology and pathology. 15 The decreased expression of Tet2 has been shown in human atherosclerosis. 25 The Tet2 hypermethylation observed in our study emerges as another acceptable mechanism to explain persistently reduced Tet2 expression in atherosclerosis. In addition, Liu et al 25 documents that induction of Tet2 in VSMCs is capable of converting 5-mC to 5-hmC at promoters of smooth muscle-myosin heavy chain, SRF, and Myocardin and lifts the repression of gene expression. Conversely, our study finds that the Myocardin is the major transcription factor regulated by DNA methylation in vivo because we only observe that a decrease in 5-mC is concomitant with an increase in 5-hmC at promoter of Myocardin after 5-aza treatment, although smooth muscle-myosin heavy chain and SRF are not found similar changes in atherosclerotic aorta.
Another goal of our study is to identify specific DNMT enzyme involved in atherosclerosis for subsequent functional analysis. In mammalian cells, DNMTs have 3 isoforms: DNMT1, DNMT3a, and DNMT3b. DNMT3a and DNMT3b mediate de novo DNA methylation, whereas DNMT1 acts on newly synthesized DNA to maintain methylation marks. 16 Although both DNMT1 and DNMT3a localize within plaques and are upregulated after vascular injury or PDGF treatment, 5-mC content is decreased exclusively through knockdown of DNMT1 but not affected by knockdown of DNMT3a. In accordance with in vivo observations, 5-aza treatment or DNMT1 silencing by siRNA recovers Myocardin expression, thereby inhibiting VSMC dedifferentiation, proliferation, and migration. Nevertheless, it is worth noting that DNMT3a, but not DNMT1, is shown to be associated with oxidized-low-density lipoproteininduced inflammation and hypoxia-induced matrix damage in VSMCs in a previous study. 33 Although this finding seems to contradict our results, it should be mentioned that our study focuses only on VSMC phenotype modulation induced by PDGF. The difference with our study suggests that each DNMT is regulated by specific stimuli and plays different roles in the process of atherosclerosis. Nonetheless, because knockdown of DNMT3a mediated by siDNMT3a only partially inhibits DNMT3a expression, we could not conclusively preclude the role of DNMT3a on VSMC functions. The other limitation of our study is that we cannot totally exclude the possibility that 5-aza may alter the DNA methylation of other relevant cell types for vascular remodeling such as endothelial cells. 23 However, the in vitro experiments in SMCs confirm that the methylation condition will affect SMC phenotype definitely. Strong evidence and our findings consistently indicate that drifts in global DNA methylation concur with aging. 34, 35 Albeit 5-hmC comes from 5-mC and acts as an intermediate during active demethylation, 5-hmC levels fluctuate during mouse preimplantation development and vary from tissue to tissue. 26 In this regard, our work uncovered that 5-hmC accumulated, coinciding with a reduction in 5-mC, in normal aorta but remained unchanged in atherosclerotic aorta. This discrepancy could be attributed to Tet2 hypermethylation and inactivation in atherosclerotic aorta, which ultimately limited 5-hmC conversion. About gene-specific methylation, our results demonstrate that Tet2 hypermethylation is secondary to atherosclerosis, although most of previous studies looking across the genome suggest that disease-associated DNA methylation could arise before cancer onset. 33 It is, thus, A and B, The efficiencies of small interfering RNA (siRNA)-mediated DNMT1 and DNMT3a silencing were confirmed by Western blot. *P<0.05. C, Rat aortic smooth muscle cell (RASMCs) were transfected with DNMT1 siRNA followed with platelet-derived growth factor (PDGF) treatment (20 ng/mL), and cell proliferation was assayed by CellTiter 96 aqueous one solution cell proliferation assay. C, Representative images of wound healing assay. D, The extent of wound healing was calculated as the percentage of remaining cell-free area compared with the original wound area. *P<0.05. E. The mRNA expression levels of smooth muscle action (SMA), smooth muscle-myosin heavy chain (SM-MHC), and Myocardin in RASMCs transfected with DNMT1 siRNA followed with PDGF treatment (20 ng/mL) were measured by quantitative polymerase chain reaction. *P<0.05 vs siCtr plus PDGF treatment group. Each experimental data point was performed in triplicate. conceivable that prolonged environmental exposure initiates and exacerbates atherosclerosis, as well as Tet2 methylation.
Conclusions
DNMT inhibition prevents VSMC dedifferentiation, proliferation, and migration in vitro and eventually retards vascular remodeling and atherosclerosis. The underlying mechanisms depend on a passive demethylation pathway via suppression of global 5-mC content and Tet2 hypomethylation, which in turn initiates an active demethylation pathway, characterized as enrichment of 5-hmC in the Myocardin promoter. Therefore, stringent control of the yin-yang equilibrium of DNA methylation is critical to VSMC phenotypic modulation and artery protection. 
